{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-221604","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.659300+00:00","generated_at":"2026-06-11T03:47:22.034850+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody","bullets":["On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).","Novartis will cease enrolling patients in remaining active TGFß clinical studies and collect final data.","XOMA licensed NIS793 to Novartis in September 2015; no milestones or royalties mentioned in the filing.","NIS793 is investigational; efficacy/safety not established and no guarantee of commercial availability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-221604","json":"https://secwatch.observer/filing/0001193125-23-221604.json","markdown":"https://secwatch.observer/filing/0001193125-23-221604.md","text":"https://secwatch.observer/filing/0001193125-23-221604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/0001193125-23-221604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/d528666d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T03:47:22.034850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}